Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: a systematic review and cost-effectiveness analysis

Matt Stevenson,1* Tim Gomersall,1 Myfanwy Lloyd Jones,1 Andrew Rawdin,1 Monica Hernández,1 Sofia Dias,2 David Wilson3 and Angie Rees1

1School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK
2Centre for Academic Primary Care, University of Bristol, Bristol, UK
3Oxford University Hospitals, Oxford, UK

*Corresponding author

Declared competing interests of authors: David Wilson undertakes clinical practice in cement augmentation of the spine in both the NHS and the private sector.

Published March 2014
DOI: 10.3310/hta18170

Scientific summary

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty
Health Technology Assessment 2014; Vol. 18: No. 17
DOI: 10.3310/hta18170

NIHR Journals Library  www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Osteoporosis is a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a resulting increase in bone fragility and susceptibility to fracture. The clinical significance of osteoporosis lies not in low bone mass per se but in the fractures that may occur as a consequence. In vertebral fracture, one or more vertebrae are compressed, leading to a reduction in height and potentially also to abnormal curvature of the spine (kyphosis). Vertebral compression fractures (VCFs) can lead to severe acute and chronic pain, impaired mobility and reduced quality of life. They have also been linked to poor cardiopulmonary function and appetite, and an increased risk of mortality. Although VCFs are thought to be common, it is difficult to give a precise estimate of prevalence and incidence as the majority remain undiagnosed. When painful VCFs do come to clinical attention, they are typically treated with optimal pain management (OPM) consisting of analgesics, bed rest and back bracing. However, this approach is unsatisfactory for a proportion of patients and, when used as a longer-term treatment, can lead to exacerbation of the underlying osteoporosis.

Percutaneous vertebroplasty (PVP) is a minimally invasive surgical procedure in which bone cement (such as polymethylmethacrylate, glass polymers, hydroxyapatite and calcium phosphate) is injected into a fractured vertebra under radiological guidance using fluoroscopy. The procedure is usually performed under intravenous sedation or light general anaesthesia. A disposable bone biopsy needle or trocar needle is placed centrally in the vertebral body using an image-guided safe access route. This may be done bilaterally through the pedicles, oblique across one pedicle or lateral oblique through the base of the pedicle. The cement is then injected very slowly, again under constant fluoroscopic guidance.

Percutaneous balloon kyphoplasty (BKP) is a variation of this approach, in which an inflatable balloon tamp is placed in the collapsed vertebra prior to cement injection in order to create a cavity allowing low pressure injection. A potential advantage of kyphoplasty is that it may partially correct the reduction in vertebral height; however, the degree of height restoration may be none or minimal. Early case reports, retrospective case series and quasi-experimental studies suggested that these procedures led to dramatic improvements in pain and physical functioning. Furthermore, there are plausible biomechanical reasons that may account for these improvements, such as stabilisation of the collapsed vertebra, correction of kyphotic deformity and height restoration. However, two recent double-blind, operative placebo with local anaesthetic (OPLA) controlled trials of PVP suggest that the procedure may provide no greater benefits than administration of local anaesthetic to the affected area.

Objectives

The objective of this review was to systematically evaluate and appraise the clinical effectiveness and cost-effectiveness of PVP and BKP in reducing pain and disability in people with osteoporotic VCFs in England and Wales. The study also included a narrative review of safety.

Methods

A systematic search of databases including MEDLINE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, EconLit, The Cochrane Library, and Database of Abstracts of Reviews of Effects (DARE) was conducted with a cut-off date of November 2011. Search terms included ‘vertebroplasty’, ‘kyphoplasty’, and a broad variety of related clinical terms. Studies met the inclusion criteria if they were randomised controlled trials (RCTs) including people of any age and either sex with
painful osteoporotic vertebral compression fractures. The intervention groups of these trials must have received PVP or BKP, and the comparators were the interventions themselves, conservative management, or defined as sham surgery. Primary outcomes were health-related quality of life, back-specific functional status/mobility, pain/analgesic use, vertebral body height and angular deformity, incidence of new vertebral fractures, and progression of treated fracture. Safety was assessed in a narrative review including data from the RCTs of PVP and BKP along with large case series (≥200) and individual case reports of complications.

Data were extracted independently by two reviewers using a standardised data extraction form; discrepancies were resolved by discussion. The quality of the included studies was critically assessed by the same two reviewers using a tool based on the criteria proposed by the Centre for Reviews and Dissemination and the Cochrane Collaboration for assessing the risk of bias in randomised trials, and also including some vertebral augmentation-specific items.

Owing to the potential impact of baseline imbalances in the degree of pain and disability reported by patients with osteoporotic VCFs, outcomes that were reported as continuous data were assessed in terms of the difference between the mean changes from baseline in the intervention and control groups, rather than absolute differences at any time point. For dichotomous outcomes, relative risks, with confidence intervals and p-values, were calculated using The Cochrane Collaboration’s Review Manager software (version 5.1, The Nordic Cochrane Centre, Copenhagen, Denmark) if such data were not reported by the study investigators. Where appropriate, a meta-analysis was carried out with random effects models, using Review Manager. However, such meta-analysis was limited to dichotomous outcomes. It was not considered appropriate to undertake a meta-analysis of continuous or quasi-continuous outcomes because a previous meta-analysis of individual patient data from the two double-blind OPLA-controlled trials has already been published. Where meta-analysis was not possible, published data were tabulated and discussed in a narrative review.

Medtronic provided observational data indicating that vertebral augmentation may be associated with a beneficial mortality effect, and that potentially BKP was more efficacious than PVP. The clinical hypothesis for this effect is that as patients become more mobile more quickly, the (typically elderly) patients are less prone to infection. These data were formally critiqued.

A mathematical model was constructed to explore the cost-effectiveness of BKP, PVP (using low-viscosity cement in 85% of patients and high-viscosity cement in 15% of patients) and OPLA compared with OPM. Owing to uncertainty in the evidence base, six scenario analyses were conducted that assessed combinations of assumptions on mortality (differential beneficial effects for BKP and PVP; equal beneficial effects for BKP and PVP; and no effect assumed) and derivation of utility data [either solely mapped from visual analogue scale (VAS) pain score data produced by a network meta-analysis or using direct European Quality of Life-5 Dimensions (EQ-5D) data from the trials]. Extensive sensitivity analyses were conducted on each of the six scenarios. Exploratory analyses were conducted on the cost-effectiveness of using high-viscosity cement in all patients, on the available costs for patient education to obtain the OPLA response while maintaining a cost per quality-adjusted life-year (QALY) gained ratio below £20,000 and on the use of initial facet joint injections.

Results

Number and quality of studies

Twenty-eight articles relating to a total of nine RCTs were identified and included in the review of clinical effectiveness. This body of literature was of variable quality, with the two double-blind, OPLA-controlled trials [Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009;361:557–68; Gray LA, Jarvik JG, Heagerty PJ, Hollingworth W, Stout L, Comstock BA, et al. INvestigational Vertebroplasty Efficacy and
SCIENTIFIC SUMMARY: PERCUTANEOUS VERTEBROPLASTY AND PERCUTANEOUS BALLOON KYPHOPLASTY

Safety Trial (INVEST): a randomized controlled trial of percutaneous vertebroplasty. BMC Musculoskeletal Disord 2007; 8:126] being at the least risk of bias. The most significant methodological issue among the remaining trials was lack of blinding for both study participants and outcome assessors. In addition, only the two OPLA-controlled trials provided adequate information on the prior training, skills and knowledge of the operators.

Summary of benefits and risks

Broadly speaking, the literature suggests that both PVP and BKP provide substantially greater benefits than OPM in open-label trials. However, in double-blind trials PVP was shown to have no more benefit than local anaesthetic; no trials of BKP compared with local anaesthesia have been conducted.

Quality of life was most often assessed with the EQ-5D and/or the Quality of Life Questionnaire of the European Foundation for Osteoporosis scales. Findings indicated greater improvements on both these measures in the open-label trials of PVP [Blasco JA, Martinez-Ferrer A, Macho Fernández J, San Roman Manzanera L, Pomés Talló J, Carrasco Jordan JL, et al. Effect of vertebroplasty on pain relief, quality of life and the incidence of new vertebral fractures. A 12-month randomised follow-up, controlled trial (published online ahead of print 3 February 2012). J Bone Miner Res 2012. doi:10.1002/jbmr.1564; Rousing R, Andersen MO, Jespersen SM, Thomsen K, Lauritsen J. Percutaneous vertebroplasty compared to conservative treatment in patients with painful acute or subacute osteoporotic vertebral fractures. Three-months follow-up in a clinical randomized study. Spine 2009; 34:1349–54; Farrokhi MR, Alibai E, Maghami Z. Randomized controlled trial of percutaneous vertebroplasty versus optimal medical management for the relief of pain and disability in acute osteoporotic vertebral compression fractures. J Neurosurg Spine 2011; 14:561–9; Voormolen MHJ, Mali WPTM, Lohle PNM, Fransen H, Lampmann LEH, van der Graaf Y, et al. Percutaneous vertebroplasty compared with optimal pain medication treatment: short-term clinical outcome of patients with subacute or chronic painful osteoporotic vertebral compression fractures. The VERTOS study. Am J Neuroradiol 2007; 28:555–60; and Klazen CAH, Lohle PNM, Jansen FH, Tielbeek AV, Blonk MC, Venmans A, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet 2010; 376:1085–92]; however, no differences in quality of life were observed in either of the OPLA-controlled, double-blind trials (Buchbinder and INVEST). Four open-label studies [Farrokhi, Rousing, VERTOS II and Wardlaw, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet 2009; 373:1016–24] found significantly greater improvements in pain among the operated cohorts, while the double-blind trials found no or a small non-significant benefit. Although there was a trend towards greater pain reduction in the PVP group in one of these OPLA-controlled trials (the INVEST study), this may have been confounded by a higher level of opioid use among the PVP group. With respect to analgesic use, also, there were greater reductions among non-operated patients in the open-label trials, while no significant between-group differences were seen in the double-blind trials. In a head-to-head trial of PVP and BKP (Liu JT, Liao WJ, Tan WC, Lee JK, Liu CH, Chen YH, et al. Balloon kyphoplasty versus vertebroplasty for treatment of osteoporotic vertebral compression fracture: a prospective, comparative, and randomized clinical study. Osteoporos Int 2010; 21:359–64), VAS pain scores did not differ significantly between the treatment groups.

There were no data on restoration of vertebral body height or kyphotic wedge angle that could be compared between studies. However, the one trial that undertook a comparison of PVP and BKP (Liu) suggests that BKP may be the more effective method. Only one study comparing BKP with OPM was identified (FREE). This suggested that BKP is more effective for reducing pain, and improving back-related functional ability and quality of life. However, the methodological limitations of this study – most notably lack of blinding and unexpected imbalances in dropout – made it difficult to draw inferences with any confidence.

Known complications of PVP and BKP include pulmonary embolism, periprocedural hypotension, radiculopathy, damage to surrounding tissue, paraparesia, paraplegia, rib fracture and postoperative
infection. Most of these complications are associated with the leakage of bone cement outside the treated vertebra. Although intradiscal leakage is unlikely to lead to complications, epidural leakage can have serious consequences, and a number of procedure-related deaths have been reported. Incidence of serious complications is rare, but the long-term implications of clinically silent cement leakages and pulmonary emboli remain poorly understood.

A meta-analysis of mortality rates suggested that PVP might be associated with reductions in mortality. However, this effect failed to reach statistical significance and the included trials were not designed to detect this outcome. A formal analysis of mortality data undertaken within this report concludes that it is possible that there is a causal difference in mortality between patients treated using OPM and patients receiving BKP or PVP given the size of the effect. Appropriately taking into account the potential endogeneity of the treatment would tend to reduce the point estimate of the effect size but may or may not eliminate it completely. It is not possible to say with certainty if there is a difference in mortality between patients undergoing BKP and PVP owing to the treatment based on the data presented. There is also considerable uncertainty, were BKP and PVP assumed to have a mortality benefit, as to whether or not OPLA would also produce a mortality benefit.

The cost-effectiveness ratios of the interventions were driven by the scenario chosen. If a differential mortality effect was chosen, then BKP consistently had a cost-per-QALY-gained ratio below £20,000. If a pooled beneficial effect was used then PVP consistently had a cost-per-QALY-gained ratio below £10,000. Where no mortality effect was assumed then the derivation of utility influenced the results. Using the EQ-SD values mapped from VAS pain scores produced by a network meta-analysis, PVP typically was the dominant intervention or had a cost-per-QALY-gained ratio below £15,000 with the exception of when a number of parameters were altered that did not favour PVP. When data from the two high-quality blinded trials (Buchbinder et al. and INVEST) were used then the cost-per-QALY-gained ratios for PVP and BKP were often greater than £20,000, depending on the other assumptions made.

The exploratory analyses indicated that the use of high-viscosity cement in all patients was unlikely to have a cost-per-QALY-gained value below £20,000, that sums in excess of £500 (and potentially considerably more) per patient could be spent to achieve the OPLA response rather than undertaking PVP and that an initial facet joint injection prior to vertebral augmentation appeared a sensible option.

**Discussion**

**Strengths, limitations of the analyses and uncertainties**

To our knowledge, this is the first systematic review to undertake a comprehensive clinical effectiveness and cost-effectiveness analysis of PVP and BKP for the treatment of osteoporotic VCFs. The clinical effectiveness analysis included RCTs only, and provided an overview of the complications that may arise from these procedures. However, the internal validity of the included literature was compromised by widespread lack of blinding. To date, there has been only one open-label trial that has compared BKP with conservative management, and so the effectiveness of this procedure was particularly difficult to establish. The use of subjective ratings of pain as an outcome measure may be confounded by various psychosocial and patient-level factors. Important questions that are yet to be convincingly addressed include the effect of vertebral augmentation on mortality and on correction of vertebral body height and kyphotic deformity. The analyses conducted the most robust mapping of VAS to EQ-SD of which we are aware, and undertook a network meta-analysis of the VAS data. Extensive scenario and sensitivity analyses were conducted to explore a wide range of different assumptions. Insufficient evidence, particularly on the impact of BKP, PVP and OPLA on mortality rates, means that no definitive conclusion can be made.

**Generalisability of the findings**

This review was specific to the population of people with painful osteoporotic VCFs; hence, the results are not necessarily generalisable to VCFs of other origins (e.g. multiple myeloma, traumatic, metastatic...
deposits). Most studies did not present data on the ethnic composition of their samples or discuss the implications of this for generalisability. Furthermore, the procedures reported in those studies were usually performed by experienced personnel, and therefore their results may differ from those obtained by less experienced practitioners. On the other hand, the age and sex make-up of the study samples was fairly representative of the wider population of people with osteoporotic VCFs. A higher proportion of females took part in the trials (typically around 70%) and the mean sample age was usually early to mid-70s.

**Conclusions**

For people with painful osteoporotic VCFs refractory to analgesic treatment, PVP and BKP perform significantly better in unblinded trials than OPM in terms of improving quality of life and reducing pain and disability. However, there is as yet no convincing evidence that either procedure performs better than OPLA with data from two high-quality trials (Buchbinder and INVEST). It can be argued that these procedures should not be undertaken unless the patient has failed to respond to a facet joint injection.

It is possible that BKP and PVP may lead to reductions in mortality and at different levels of effect; however, this possibility was derived from registry data and without information on the causes of death in these cohorts, and in the absence of randomisation, it was not possible to conclusively establish a causal link. There were no data to analyse whether or not OPLA would also be associated with mortality benefits. If such benefits exist then the cost per QALY gained of the interventions compared with OPM would be low.

Although complications associated with PVP and BKP are rare, they can be serious, and procedure-related deaths have been reported.

**Suggested research priorities**

- There is yet to be a double-blind, placebo-controlled trial of BKP. A well-designed study comparing BKP with OPLA should be considered.
- There are questions as to whether or not postoperative pain and quality of life improvements from PVP and BKP arise from a placebo response or the specific efficacy of the procedures. It may be that the failure of PVP to demonstrate greater benefits than OPLA suggests placebo efficacy only. Alternatively, it may be that the infusion of local anaesthetic has specific mechanisms of efficacy over conservative treatment. RCTs comparing local anaesthesia with OPM, and multiarm RCTs comparing vertebral augmentation, local anaesthesia, facet joint injection, patient education and OPM, would provide useful data.
- The effect of vertebral augmentation on mortality is an important yet inadequately understood issue. Large-scale registry data from Germany and the USA suggest that people with osteoporotic VCFs who have received augmentation have significantly improved survival rates; however, a definitive causal link could not be established. The effect of augmentation on mortality, and the impact of various extraneous variables, should be investigated through further retrospective case series with more details on causes of death. Ideally, this outcome would be explored in a well-controlled RCT. However, the sample size and length of follow-up required to detect meaningful differences would make such a trial difficult to perform.
- The length of stay associated with patients receiving OPM, PVP and BKP is not known with certainty, with the pivotal trials suggesting that the length of stay is considerably shorter than hospital database values. A prospective study to record such values would be beneficial.
- Sagittal balance and spinal deformity have a substantial impact on quality of life and fracture-related disability. However, the effectiveness of PVP and BKP in restoring these morphometric parameters is yet to be studied in high-quality studies.
Study registration

The study is registered as PROSPERO number CRD42011001822.

Funding

The National Institute for Health Research Health Technology Assessment programme.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: www.hta.ac.uk/

This report

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 10/122/01. The protocol was agreed in October 2011. The assessment report began editorial review in August 2012 and was accepted for publication in December 2012. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2014. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of Health Technology Assessment and NIHR Journals Library

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Health Sciences, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Honorary Professor, Business School, Winchester University and Medical School, University of Warwick, UK

Professor Jane Norman  Professor of Maternal and Fetal Health, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professorial Research Associate, University College London, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk